May 31st 2012
£4195 / $6500 / €5000
In November 2011, the International Diabetes Federation (IDF) released data showing that the number of people living with diabetes globally had reached 366 million. The IDF estimates that the number will reach 552 million by 2030 if no urgent action is taken. This equates to approximately three new cases every 10 seconds or almost 10 million a year.
There are as many as 183 million people unaware that they have diabetes, including at least 78% of people with diabetes in Africa. In some of the poorest regions in the world, where infectious diseases have traditionally been the focus of healthcare systems, diabetes cases are expected to increase by 90% by 2030.
While most of the increase in diabetes prevalence is associated with the Type 2 form, the IDF also estimates there is a 3% increase annually in Type 1 diabetes in children aged under 15. Its data show there were 490,100 children in this age group globally with the condition in 2011 and the number of cases is rising by 77,800 annually.
The human cost
According to the World Health Organisation, 50% of people with diabetes die of cardiovascular disease, primarily heart disease or stroke. After 15 years of diabetes, approximately 2% of people become blind and about 10% develop severe visual impairment. In addition, 10 to 20% die of kidney failure, while diabetic neuropathy affects up to 50% of people with diabetes.
A global challenge
Although seen as a problem mainly affecting Western countries, in fact, 80% of people with diabetes live in low and middle income countries. The IDF estimates that the Western Pacific Region had the highest number of people with diabetes aged 20 to 79 years, at 132 million, while the African Region had the smallest number, at 15 million in 2011. However, the region with the highest comparative prevalence was the Middle East and North Africa, at 11%, followed by the North America and Caribbean Region, at 10.7%. Prevalence in the Western Pacific Region was significantly lower, at 8.3%, while prevalence in the Europe region was 6.7%, representing the lowest after Africa.
Monitoring and treatment – critical components in disease management
Successful diabetes management is dependent on being able to accurately monitor blood glucose levels. That requires a range of both clinician and patient devices that are accurate, reliable and convenient. In addition, products that enable simple and convenient insulin delivery are needed by the quarter of diabetes patients that are insulin-dependent. The burgeoning diabetes burden represents a fast growing market place for companies who can supply those products.
"Who owns the rights to this technology? What trends are emerging? These and other questions are answered in this unmatched 2-volume report. Published by Espicom and UBM TechInsights, the report brings together their expertise to produce a study of insight and value."
Use this report to...
Who should read this report
A high growth and resilient market
The diabetes care market has historically exhibited strong growth, leading global sales volumes to have increased from US$8.6 billion in 2005 to US$12.4 billion in 2011. This increase is generally being driven by the increasing prevalence of diabetes, the introduction of higher-priced newer technologies such as continuous glucose
monitoring, changing trends in the management of diabetes, and the development of healthcare systems of emerging markets in recent years.
Having experienced strong annual growth in the period before 2009, the market slowed considerably, rising by just 1% in that year and by 2% in 2010. Although most product areas continued to generate strong sales volumes, this lower growth was due to weakness in the self monitoring blood glucose market as a result of lower sales volumes and pricing pressure in the US due to the economic slowdown.
Since 2010, the diabetes care market has once again picked up, rising by 6% in 2011. This improvement has been due to renewed growth for self monitoring blood glucose (SMBG) products, helped by new product launches in the US but, mainly due to strong demand in emerging markets. The growth rates in the insulin delivery segment
slowed slightly during the year due to pricing pressure for pen needles and a slight slowdown in insulin pump sales as a result of the negative economic environment.
Prospects for new market entrants
Although the diabetes devices market comprises close to 100 companies, it is dominated by just six major manufacturers: Roche, Johnson & Johnson (J&J), Bayer, Medtronic, Abbott and Becton Dickinson. Given the importance of SMBG in the overall diabetes device market, it follows that most of these companies owe their strong market position to offerings in this area, where brand recognition and a strong sales and marketing presence are vital. Although the significant market positions of the top six companies imply there is little room for smaller companies, there do remain good
opportunities for companies with unique products or devices that compete in yet-to-be established markets.
For example, Insulet has grown its sales from just US$4 million in 2006 to nearly US$120 million in 2011 as a result of offering a unique insulin pump with significant benefits over those offered by the established market leaders. Its OmniPod was the world’s first tubing-free insulin pump, meaning it is smaller than many other devices; can be worn more discreetly; eliminates interruptions in insulin delivery due to
tubing kinks, leaks or disconnections; and, enables patients to move, dress, sleep and exercise more easily.
A forensic investigation of 5,900 patents in the diabetes device area has been distilled to provide a detailed assessment of who holds key technology patents worldwide.
This volume provides an in-depth analysis of the technologies and IP associated with diabetes devices, including:
There are a significant number (over 500) of patent assignees. This report provides detailed analysis of:
Investigation of assignee by technology group and forward citations of key patents provides insight into the large number of players and identifies potential targets for acquisition.
The patent holding and status of the following companies is covered in great detail:
This unprecedented combination of market, technology, and intellectual property information will provide a detailed look at the market and devices in this space as well as provide a perspective of the challenges and opportunities associated with diabetes.
This report has been produced by two of the best names in the business!
This report is the result of a collaborative venture between UBM TechInsights and Espicom Business Intelligence, each party bringing its own skills and knowledge to provide an unmatched analysis.
UBM TechInsights is the leading provider of sophisticated information and advice to technology firms. Companies in need of technical analysis and IP management consulting rely on our deep expertise in the underlying technologies used in today’s medical devices.
For further information www.ubmtechinsights.com/medical
Espicom Business Intelligence
Espicom is a highly-regarded and established independent provider of business intelligence services for the global medtech industries. Based in the UK and with over 30 years of continuous research and editorial experience in the global health industry, Espicom is one of the longest established, independent business intelligence providers operating today.
Espicom produces original analysis, news and forecasts using its skilled and experienced team of full-time in-house analysts, researchers and editorial experts. Over 50,000 users
in more than 50 countries worldwide rely on Espicom’s essential market data.
For further information www.espicom.com/medical